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CD4 T-cells recognize peptide antigens, in the context of
human leukocyte antigen (HLA) class II molecules (HLA-II),
which through peptide-flanking residues (PFRs) can extend
beyond the limits of the HLA binding. The role of the PFRs
during antigen recognition is not fully understood; however,
recent studies have indicated that these regions can influence
T-cell receptor (TCR) affinity andpHLA-II stability.Here, using
various biochemical approaches including peptide sensitivity
ELISA and ELISpot assays, peptide-binding assays and HLA-II
tetramer staining, we focused on CD4T-cell responses against
a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4),
which have been associated with improved control of colorectal
cancer. Despite their weak TCR-binding affinity, we found that
anti-5T4 CD4 T-cells are polyfunctional and that their PFRs
are essential for TCR recognition of the core bound nonamer.
The high-resolution (1.95 Å) crystal structure of HLA-DR1 pre-
senting the immunodominant 20-mer peptide 5T4111–130, com-
bined with molecular dynamic simulations, revealed how PFRs
explore the HLA-proximal space to contribute to antigen reac-
tivity. These findings advance our understanding of what con-
stitutes anHLA-II epitope and indicate that PFRs can tuneweak
affinity TCR–pHLA-II interactions.
CD4 T-cells orchestrate immune responses to antigens
through the binding of highly variable  T-cell receptors
(TCRs)5 to peptide epitopes presented on major histocompat-
ibility class II (MHC-II or in humans HLA-II) molecules. Such
peptide epitopes are often derived from internalized proteins
that are digested to short peptides in a specialized endocytic
antigen-processing pathway (reviewed in Ref. 1). HLA-II mol-
ecules loaded with such peptides (pHLA-II) are mainly
expressed by professional antigen-presenting cells (APCs),
which sample the periphery for extracellular antigens of poten-
tial immunogenicity. Through this pathway, CD4T-cells have
been shown to play an important role in tumor surveillance (2).
Due to the open-ended nature of the peptide-binding groove
of HLA-II, compared with the closed groove of HLA-I, loaded
peptide epitopes can vary in length typically between 12 and 20
amino acids (3). Thus, outside of the 9-amino acid “core” bind-
ing region, HLA-II peptides can extend out of the binding
groove, forming peptide-flanking residues (PFRs). Structurally,
based on the limited available data, PFRs tend to continue a
linear extension out of the HLA-II–binding groove for 1 to 2
residues (reviewed in Ref. 4), whereas longer PFRs can extend
away from the HLA surface (5) and form a secondary structure
(6).
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Murine models have shown the presence of PFRs influences
peptide–MHC-II stability (7), T-cell activation (8), TCR gene
usage (9), and TCR specificity (10). In humans, processed pep-
tide antigens eluted from HLA-II frequently contain PFRs (3,
11), are recognized by human CD4 T-cells (6, 12) and can be
utilized to enhance TCR binding affinity through modification
(13). Molecular understanding of how PFRs may enhance
HLA-II and/or TCR binding is limited, which makes defining
HLA-II–restricted epitopes challenging compared with HLA-
I–restricted epitopes (14).
The role of PFRs during CD4 T-cell recognition of cancer
epitopes has not been well-defined and may represent an
opportunity to design optimized peptides for vaccine or other
therapeutic approaches. Here, we focused on understanding
how PFRs might influence CD4 T-cells to the oncofetal anti-
gen 5T4, which is up-regulated in a number of epithelial-de-
rived cancers (15) including colorectal cancer (CRC) (16). We
have shown 5T4-specific CD4T-cells are associated with bet-
ter control of CRC in situ (17) and that vaccine-boosted 5T4-
specific T-cells lead to improved survival of patients (18).
We have previously examined the functional characteristics
ofHLA-DR*0101 andHLA-DR1*0101 (henceforthDR1)-re-
stricted CD4 T-cells recognizing influenza A virus (IAV)
hemagglutinin (13, 19). To compare characteristics, we isolated
three human HLA-DR1–restricted CD4 T-cell clones that
recognized regions of 5T4 that generate T-cell responses across
multiple subjects (20). Through cellular analyses on theseHLA-
DR1–restricted T-cell clones, we investigate the recognition
profile of different regions of the 5T4 protein. By combining
structural analysis with cellular screening of peptide trunca-
tions/substitutions, we further dissect the immunogenicity of
specific regions within a 20-mer 5T4 peptide epitope. Here, we
show PFRs enhance peptide-HLA binding and activation of a
cognate T-cell clone and use molecular dynamics simulations
to explore how PFRs may enhance immunogenicity. Together,
we show PFRs play a fundamental role in driving T-cell activa-
tion, supporting the notion that manipulating PFRsmay gener-
ate more effective therapeutic anti-cancer immunity.
Results
CD4 T-cell clones selected against immunodominant 5T4
epitopes exhibit relatively low sensitivity
CD4T-cell responses to 5T4-derived peptide antigens have
been detected in the periphery of healthy donors and patients
with CRC (17) where peptide epitopes presented by HLA-II
alleles have been mapped (20). To characterize further this
response to 5T4, we generated CD4 T-cell clones from an
HLA-DR1 donor to three mapped immunodominant 5T4-
derived 20-mers. These clones were selected on function (IFN-
) in response to peptide presented by T2 cells (21) trans-
duced with HLA-DR1 (T2-DR1) (22). CD4 T-cell clones
reactive to three epitopes were obtained: 5T411–30-reactive
(GD.D821), 5T4111–130-reactive (GD.D104), and 5T4371–390-
reactive (GD.C112) (Fig. 1).
Each clone responded in T-cell activation assays by produc-
ing IFN- and TNF in response to peptide where one or both
cytokines were detectable down to 106 M concentration of
peptide. Each clone also produced the early marker of activa-
tion MIP-1 (CCL4) down to 106-107 M peptide. Although
each 5T4 cancer antigen-reactive clone exhibited similar reac-
tivity, this sensitivity wasmarkedly inferior (100-fold weaker)
to CD4 T-cell clones recognizing pathogen-derived epitopes
(representative example to IAV hemagglutinin306–319 epitope
shown). Despite this far weaker sensitivity, cross-recognition of
irrelevant 5T4 peptides was not detected (Fig. S1).
CD4 T-cell clone reactivity can occur despite undetectable
TCR binding
To identify the HLA restriction of each clone, low T-cell
numbers (300 T-cells) were stimulated overnight with peptide
plus various APCs and assayed by IFN- ELISpot. Each clone
was responsive to tumor-derived peptide presented by a auto-
logous (HLA-II) B lymphoblastoid cell line (data not shown)
or T2-DR1 cells in co-culture IFN- ELISpot assays (Fig. 2A).
This reactivity was inhibited by anti–HLA-DR blockade and no
such activation was observed using T2-WT (HLA-II) as pre-
senting cells. Assessment of in vitroHLA-DR1 binding showed
two of the 5T4 peptides (5T411–30 and 5T4111–130) bound to
HLA-DR1 at reasonable affinities (IC50  535 and 176 nM,
respectively) although weaker compared with the universal
IAV epitope HA306–319 (IC50  13 nM) suggesting that pep-
tide-HLA binding may at least in part affect cognate clone sen-
sitivity (Fig. 2B).
We attempted to detect GD.D821, GD.D104, and GD.C112
engagement of cognate HLA-DR1 presented ligand via
enhanced multimer staining techniques previously used to iso-
late weak avidity T-cell clones (23–25). Despite these protocols,
detectable engagement of HLA-DR1–5T4 multimers to
GD.D821, GD.D104, and GD.C112 cells was repeatedly barely
above background,with onlyGD.D821 exhibiting limited stain-
ing compared with irrelevant controls (Fig. 2C). This was
despite high surface TCR expression by all 5T4-reactive
clones (Fig. S2). Such detection was in stark contrast to IAV-
specific clones using the same methodology (Fig. 2C and Ref.
13). Thus, despite peptide specificity, detectable engage-
ment of cognate ligand could not be revealed by current
HLA-II multimer flow cytometry, suggesting the peptide-
responsive TCRs may bind their ligand at extremely low
affinity. Indeed, binding of soluble GD.C112 TCR to cognate
pHLA-II could also not be detected by surface plasmon res-
onance (data not shown).
Structure of the 20-mer HLA-DR1 5T4111–130 epitope
demonstrates extended PFR conformations
To gain mechanistic insight into the observed reactivity to
tumor-derived antigen, we next sought to investigate the pres-
entation of these epitopes structurally. Generation of TCR–
pHLA-II co-complex crystals for the three 5T4 epitope-TCR
systems proved unsuccessful, likely due to low receptor-ligand
affinity. We did, however, determine the crystal structure of
HLA-DR1 in complex with the full-length 5T4111–130 20-mer
peptide at 1.95 Å resolution (Table 1 and Fig. 3A). 5T4111–130
bound via a near-typicalHLA-DR1bindingmotif incorporating
Leu-1, Leu-4, Ala-6, and Leu-9 at P1, P4, P6, and P9 as anchor
residues, respectively (Fig. 3B). This registerwas themost prob-
PFRs influence CD4 T-cell response to 5T4
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able core-binding region predicted by NetMHCIIpan (26) (Fig.
S3A). In addition, unbiased omit map analysis provided no evi-
dence of partial occupancy that may result due to register shift-
ing of the epitope (Fig. 3C). This therefore defined the core
nonamer-binding region of the immunogenic peptide as
5T4117–125 (FARRPPLAELAALNLSGSRL; underlined) flanked
by six N-terminal PFRs, henceforth N-PFRs (FARRPP) and five
C-terminal PFRs, henceforth C-PFRs (SGSRL). Deterioration
of electron density at the N and C termini caused an increase in
assigned isotropic displacement B-factors within the three
mostN-terminal residues (FARRPP-) and twomostC-terminal
residues (-SGSRL), suggesting that these PFR regions exhibit
high flexibility (Fig. 3D). As a result, the N-terminal Phe-(6)
residue could not be modeled due to a lack of discernible con-
tinuous electron density (Fig. 3E).
PFRs can contribute to HLA anchoring
Crystallization of HLA-DR1–5T4111–130 with the full-length
unlinked 20-mer peptide represented an opportunity to ana-
lyze the role of PFRs in HLA-II presentation and the gener-
ation of the functional epitope. Interestingly, we observed
contrasting features at each terminus, whereby the N-PFR
largely nestled along the -DR chain, whereas the C-PFR
elevated away from the HLA. Such features were accompa-
nied by a differing degree of contacts by N- and C-PFRs to
the HLA (Fig. 4A). Of the 11 PFRs, five residues contributed
to peptide binding to HLA-DR1: N-PFR Arg-(3), Pro-(2),
and Pro-(1), as well as the C-PFR Ser-10, Ser-12, and
Leu-14 (FARRPPLAELAALNLSGSRL; highlighted in bold,
core peptide underlined).
Figure 1. Impaired peptide sensitivity of 5T4-reactive CD4 T-cell clones. Soluble IFN-, TNF, and MIP-1 release by three 5T4-responsive CD4 T-cell
clones and a representative influenza A virus hemagglutinin (IAV-HA)-responsive CD4 T-cell clone. Cytokine/chemokine measured by ELISA in response to
overnight co-culture with T2-DR1–presenting cells and titrated cognate peptide. Representative examples (mean S.D.) of two independent experiments
were performed in at least duplicate is shown.
PFRs influence CD4 T-cell response to 5T4
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Enumeration of such contacts, however, showed a dramatic
drop-off in contacts past Arg-(3) and Ser-10 within the N-
and C-PFRs, respectively (Table 2 and Fig. 4B). N-PFRs made
nearly 3-fold more contacts with the HLA compared with the
C-PFRs. This was mediated by two consecutive prolines (Pro-
(1) and Pro-(2)), which incorporated a di-proline kink that
positioned theN-PFR adjacent to the2 domain of the peptide-
binding groove (Fig. S4). Interestingly, despite being outside the
core-binding region, Arg-(3) displayed the largest number of
inter-molecular contacts out of any other peptide residue by
contacting five consecutive -DR residues: Gly-49–Ser-53
(Table S1). These included 23 van der Waals contacts between
the Arg-(3) peptide backbone (3 contacts) and side chain (20
contacts) atoms (Fig. 4C). Moreover, Arg-(3) was engaged in
three short distance (2.75–3.0 Å) hydrogen bonds with -DR,
two from the side chain amine (-NH2) of Arg-(3). Despite the
number of contacts made by PFRs to the HLA molecule, we
later show that loss or substitution of either N- or C-PFRs did
not impact markedly on peptide binding.
Lack of HLA influence on PFRs allows secondary structure
reminiscent of native whole antigen
Contacts to the HLA by C-PFRs beyond Ser-10 (P10) were
few within the crystal structure. Instead, the C-PFRs formed a
hairpin loop structure mediated primarily by intramolecular
(peptide to peptide) contacts; causing the protrusion of the pep-
tide away from the HLA binding groove’s influence and back to
the core peptide region (Fig. 4D). This secondary structure was
not stabilized by any artifactual crystal contacts (Fig. S5). The
hairpin loop formed as a result of four residues, Leu-9, Ser-10,
Gly-11, and Ser-12 (assigned i, i1, i2, and i3, respectively),
forming a tight reverse turn in the C-terminal flank of
5T4111–130. The serine/threonine (ST) character loop (27) was
stabilized via the Leu-9(i) backbone carbonyl forming a hydro-
Figure 2. 5T4 clone reactivity toHLA-DR1–presentedpeptides despite nomeasurable ligandengagement.A, IFN- ELISpot assays of clones in response
toovernight co-incubationwithpeptide-pulsedAPCs. IFN- releasewasobservedusingDR1-only (T2-DR1) butnotDR1-null (T2-WT) presenters in thepresence
of peptide but not no-peptide (media) controls. IFN- releasewas blocked by anDRblocking antibody (-DRAb). GD.D821, GD.D104, GD.C112, andDCD10
were stimulated with APCs pulsed with 105, 106, 105, and 106 M peptide, respectively. Maximal IFN- response indicated by phytohemagglutinin (PHA)
activation. Inset numbers represent raw spot forming cells (sfcs). Presented ELISpot wells representative of two duplicate experiments. B, binding capacity of
each peptide toHLA-DR1molecules in competitive binding assays in vitro. Error bars indicate S.D. of experiments performed in triplicate. Inset numberdenotes
IC50 value calculated fromdisplayed curve fit. N.D. IC50 not determined.C, cognateHLA-DR1multimer stainingof each 5T4-reactive clone exhibiting staining
marginally above background (irrelevant multimer). This was in stark contrast to typical staining of the DCD10 viral-reactive clone. Histogram representation
displays inset geometric mean fluorescent intensity of cognate -DR1 multimer (black) and irrelevant -DR1 control (gray).
PFRs influence CD4 T-cell response to 5T4
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gen bond to the Ser-12(i3) side chain hydroxyl (2.8 Å) and an
additional long-range polar interaction (3.6 Å) to the Ser-
12(i3) amide. Dihedral angles about Ser-10(i1) andGly-11(i2)
conformed to typical average values observed in type II -hair-
pin geometry (28). As a result, Leu-9(i) and Ser-12(i3)C atoms
were positioned within 7 Å.
Interestingly, examination of the native 5T4 whole protein
structure (PDB accession code 4CNM) (29) revealed that the
equivalent residues in the native 5T4 whole protein antigen
(Leu125–Ser126–Gly127–Ser128) also form an ST loop with type
II-hairpin dihedrals (Fig. 4E). Structural alignment of the L-S-
G-S sequence “in whole protein” and “in HLA” revealed struc-
tural similarity about the loop (root mean square deviation
5T4125–128 (PDB 4CNM) versus HLA-DR1–5T4125–128  0.90
Å). Thus, we conclude that PFRs can form ordered secondary
structural features, reminiscent of native antigen, allowed by a
lack of HLA influence on extended PFRs.
Highly focused specificity to the 5T4111–130 core epitope
Having observed interesting structural features within the
PFRs we next sought to decipher their importance alongside
core residues to forming the functional 5T4111–130 epitope
using truncated/substituted peptides. Given that PFRs (partic-
ularly the N-PFRs) contributed to pHLA stabilization in the
crystal structure, we assessed the contribution of residues (both
core and PFRs) in HLA-DR1–binding assays. Similarly, the
effect of these peptides on cognate T-cell clone activation
(GD.D104 IFN- ELISA) was assessed given the elevation of
C-PFRs toward potential TCR contact.
Within the 5T4111–130 core, three potential TCR contact res-
idues (Glu-3, Leu-7, andAsn-8)were individually substituted to
alanines. Despite the electrostatic and salt-bridge capacity of
Glu-3, alanine substitution had no effect on activation, how-
ever, alanine substitution of Leu-7 and Asn-8 effectively pre-
vented reactivity of clone GD.D104 (Fig. 5A); suggesting spec-
ificity of the TCR for long and polar side chain stereochemistry.
Each core mutation was not predicted to generate alternate
more probable binding registers than the WT peptide (Fig.
S3B). Alanine substitution had minimal (P7 Leu3 Ala) or no
(P8Asn3Ala) effect on peptide binding toHLA-DR1 (Fig. 5B),
demonstrating that the observed loss of GD.D104 function is
due to focused and specific binding of the TCR to a hot spot
within the 5T4111–130 core binding nonamer.
PFR residues of 5T4111–130 are required formaximal cognate
clone activation
Given the focused sensitivity of the TCR to the core bound
nonamer (LAELAALNL), it was surprising that cloneGD.D104
exhibited no T-cell activation in response to overnight stimu-
lation with the core nonamer peptide, even at extremely high
doses (104 M) of peptide (Fig. 5C). Although the core nona-
mer demonstrated weaker binding to the HLA molecule, as
might be expected (Fig. 5D), other T-cell clones had previ-
ously exhibited detectable T-cell activation to peptides with
even weaker HLA-DR1 binding ability (Fig. 2B). This sug-
gested that the PFRs played a role in facilitating TCR inter-
actions over and above some enhancement of peptide bind-
ing to HLA.
Sequential truncation of the N-PFRs resulted in a stepwise
reduction in GD.D104 activation, with N-PFR truncation
(FARRPP3 PP) requiring high doses of peptide to gain T-cell
activation (105 M) (Fig. 5E). Even removal of distal residues,
at P(5) and P(6) caused a reduction of T-cell activation.
These residues did not contribute to HLA binding (Fig. 4A) nor
is there evidence of TCR contacts to these positions in other
systems (30). The effect of C-PFR truncations was not as
marked, however, truncations still reduced T-cell activation.
This was demonstrated by requiring a 10–100–fold increase in
peptide concentrations to achieve similar levels of T-cell acti-
vation (Fig. 5G). Reduction in clone activation was not as a
result of a significant reduction in peptide binding to HLA, as
both N- and C-PFR truncations resulted in similar HLA bind-
ing (Fig. 5, F and H).
As the TCR appears more focused toward the C-terminal
half of the core peptide (P7 andP8) (Fig. 5A), reduction ofT-cell
activation byC-PFR truncationmay reflect a disruption to TCR
sensing of neighboring C-PFR structural composition, i.e. the
C-PFR-hairpin loop.Alteration of the loop by substituting the
P11 Gly 3 Arg (a nonconservative switch that would likely
disrupt the C-PFR hairpin loop by restricting dihedral angles
about P11) actually increased T-cell activation (clone sensitiv-
ity was increased30% of maximal response at 107 M peptide
compared withWT) (Fig. 5I). This increase could not be attrib-
uted to HLA binding (Fig. 5J) or change in predicted core bind-
ing frame (Fig. S3B).
Table 1
Data reduction and refinement statistics of HLA-DR1–5T4111–130
HLA-DR1–5T4111–130
Dataset statistics
Space group P 1 21 1
Unit cell parameters a 56.96, b 121.29, c 68.96
 90.0°,  107.3°,  90.0°
Radiation source DLS I02a
Wavelength 0.9795 Å
Resolution range 60.65–1.95 (2.00–1.95) Å
CC-half 0.995 (0.589)b
Total reflections 239,331 (17,960)
Unique reflections 64,792 (4,807)
Completeness 99.6 (99.8) %
Multiplicity 3.7
I/ 8.3 (1.3)
Rmerge (%) 10.0 (91.3)
Wilson B-factor (A2) 31.2
Refinement statistics
Phase determination Molecular replacement (PHASER)
No. of reflections used 64,762
No. of reflections in Rfree set 3,165
Rcryst (%) 19.31
Rfree (%) 24.11
Asymmetric unit (ASU) parameters
Number of copies in ASU 2
Number of non-H atoms 6,784
Deviation from ideal geometry (RMSD)
Bond lengths 0.0191
Bond angles 1.8659
Chiral volume 0.1086
Ramachandran statistics (MolProbity)
Most favored 756 (98.1%)
Allowed 15 (1.9%)
Outliers 0 (0.0%)
MolProbity clash score 2.42
MolProbity score 1.48
a DLS, Diamond Light Source.
b Values in parentheses represent statistical value for data in the outermost resolu-
tion shell.
PFRs influence CD4 T-cell response to 5T4
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PFRs explore the HLA proximity space inmolecular dynamics
simulations
The above results demonstrate that T-cells specific for three
different epitopes derived from the cancer antigen 5T4 express
TCRswith low affinity for the pHLA-DR1.Adetailed analysis of
clone GD.D104 activation by HLA-DR1–5T4111–130 revealed a
reliance on the PFRs for activation, yet the presence of a distinct
secondary structure within the C-terminal PFR (a –hairpin
loop) appeared redundant for T-cell activation. It is therefore
not clear as to how this TCR utilizes PFRs for binding and clone
activation.
To attempt to answer this question, we conducted all-atom
molecular dynamic (MD) simulations at the nanosecond-mi-
crosecond time scale in explicit solvent, hypothesizing that PFR
mobility not revealed by the static crystallographic data may
contribute to PFR tuning ofHLA-DR1–5T4111–130 recognition.
Ten independent simulations of 0.2 s each were performed
using the latest AMBER 16 force field, initiated from both mol-
ecules observed in the asymmetric unit.
These MD simulations suggested that both N- and C-PFRs
explore a large conformational space (Fig. 6A, Video S1). Across
the 20-mer peptide, backbone fluctuations exhibited a para-
bolic distribution (i.e. highest at termini) of root mean squared
fluctuations (RMSFC) around the time-averaged positions,
highlighting increased peptide mobility due to distance from
the core-binding region (Fig. 6B). The three most N-terminal
Figure 3. Structural characterization of the 5T4111–130 epitope presented by HLA-DR1. A, cartoon representation of HLA-DR1 (DR, blue; DR1, green)
presenting 5T4111–130 (sticks,magenta). B, assignment of the 5T4111–130 core epitope. HLA-DR1 anchor residues (gray; downward arrowheads P1, -4, -6, and -9)
and peptide flanking residues (N-PFR, light green sticks; C-PFR, cyan sticks). Potential high enthalpy TCR contact residues are highlighted (P3, green; P7, orange;
P8, red). DR1 helix blue cartoon. C, omit map analysis of differencemap peaks in the absence of peptide during refinement. Positive differencemap peaks
(green mesh; 3.0 ) and not negative peaks (red mesh; 3.0 ) exhibit highly related density to refined peptide model (magenta sticks; atoms colored: C,
magenta; O, red; N, blue). D, B-factor analysis indicating a stable core binding region (B-factor 40) flanked by stability extending to both N-terminal and
C-terminal flanking regions. Extremities of termini exhibited high flexibility (B-factors 80). E, modeled 5T4111–130 within refined electron density map
contoured at 1.0  and 0.5  (gray mesh).
PFRs influence CD4 T-cell response to 5T4
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(FAR) and C-terminal (SRL) residues exhibited high backbone
fluctuations (RMSFC; 3–7Å). As expected, residues within the
core-binding region remained significantly more rigid
(RMSFC of 0.7–1.1 Å), however, a degree of rigidity wasmain-
tained into the PFR positions proximal to the core residues,
with Arg-(3) (P-3) and Gly-11 (P11) both displaying interme-
diate RMSF of 2.1 Å suggesting maintenance of structural
features.
By analyzing the average number of peptide to HLA contacts
during the MD simulation time, a similar contact profile com-
paredwith the static crystal structurewas observedwith a slight
increase in contacts extending intomore distal PFR positions in
MD simulations (Fig. 6C). Closer examination of representative
structures from themost populated clusters extracted from the
MD simulations suggested alternative conformations whereby
PFRs may stabilize peptide-HLA binding (Fig. 6D). In the
N-PFR, Arg-(4) sampled interactions (equating to 4% of total
p-HLA contacts during the simulation time) with a consecutive
pocket of -DR residues (Gly-49–Ser-53); where no contacts
were observed in the static crystal structure (Fig. 6E). Despite
surrounding peptide mobility, Arg-(3) maintained a consid-
erable contribution (10% of total contacts in MDs) by main-
taining contact with -DR residues but also by sampling con-
formations that allowed binding to -DR1 chain residues
Gly-267 and Val-265 (Fig. 6F).
Table 2
Contribution of 5T4111–130 peptide residues to HLA binding
Peptide to HLA contacts
Residue Register vdWa H-bondsb Total
N-terminal peptide-flanking
residues
Arg-(3) P(3) 23 3 26
Pro-(2) P(2) 9 1 10
Pro-(1) P(1) 8 1 9
Peptide-binding core residues
Leu-1 P1 15 1 16
Ala-2 P2 9 2 11
Glu-3 P3 11 0 11
Leu-4 P4 21 3 24
Ala-5 P5 5 2 7
Ala-6 P6 11 1 12
Leu-7 P7 13 1 14
Asn-8 P8 9 1 10
Leu-9 P9 21 1 22
C-terminal peptide-flanking
residues
Ser-10 P10 9 2 11
Ser-12 P12 4 0 4
Leu-20 P20 1 0 1
Totals
No. of contacts with PFRs 54 7 61
N-PFRs 40 5 45
C-PFRs 14 2 16
No. of contacts with core 115 12 127
No. of total contacts 169 19 188
a vdW, van der Waals (4.0 Å cut-off).
b H-bond, hydrogen bonds (3.4 Å cut-off).
Figure4. LackofHLA influenceallowsPFR formations reminiscent of native antigen secondary structure.A,peptide toHLA contact networkmapof van
der Waals contacts (4.0 Å, gray lines) and H-bonds (3.4 Å, blue dashed lines) between the MHC1 and MHC1 residues and the 5T4111–130 peptide (core,
black; PFRs, gray). B, peptide to HLA binding contact contribution by each peptide residue. Arg-(3) contributed the most % contacts throughout the
5T4111–130 peptide. C, stick representation of the extensive contacts between Arg-(3) within the N-PFR (pink) and -DR residues 49–53 (blue). D, geometric
parameters of the C-PFR hairpin loop about Leu9–Ser12 (pink sticks). Leu-9(i) and Ser-12(i3)C atoms are distanced at 6.4 Å (black dashed line). Leu-9(i) carbonyl
hydrogen bound the Ser-12(i3) side chain hydroxyl and bound Ser-12(i3) amide (gray dashed line). Dihedral angles 	/ about Ser-10(i1) and Gly-11(i2)
conform to type II-hairpin average values:	i160°,i1120°,	i280°, i2 0°. E, equivalent residues of 5T4 (Leu
125–Ser128) in the published
structure of whole 5T4 protein (cyan sticks; PDB 4CNM) aligned and overlaid onto residues in-HLA (5T4111–130 peptide, white sticks). Geometric parameters
described in D exhibit close similarity.
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Within the C-PFR, we observed high mobility where the
C-terminal hairpin loop was maintained in 28% of the MD tra-
jectory as shown by deviation in 	,  angles at both Ser-10(i1)
and Gly-11(i2) positions ( 40° from expected type II -hair-
pin geometry). In the remaining simulation time, opening of the
hairpin loop was observed allowing contact to the HLA surface
(Fig. 6G), or potentially transient contacts toward the TCR.
This opening was mediated by an inversion of Gly-11(i2)
dihedrals (Fig. 6H). The distribution of the backbone dihe-
drals of Ser-10(i1) and Gly-11(i2) in MD simulations indi-
cated that whereas Ser-10(i1) exhibits 	/ values typical of a
type II -turn (	,   60, 120°), as observed in the static
structure, Gly-11(i2) could deviate significantly from these
expected values (	,  80, 0°). Instead, typical 	,  values of
unrestricted rotational angles explored by glycine residues
was observed (	, 60°,140° within 40° deviation) in
a significant proportion (12.1%) of trajectory frames (Fig. 6I).
Thus, the MD simulations suggest that the C-PFR is highly
mobile and can readily flip between the hairpin loop and a
flattened extended conformation in solution within the sub-
microsecond time scale. The oscillation between these two
orientations may enable this C-PFR to explore the proximal
space to facilitate interactions with both the TCR and HLA
molecule.
Discussion
CD4 T-cells have been shown to recognize 5T4-derived
antigens in humanCRCpatients and loss of this recognition has
been linked with tumor progression (17). As a result, clonal
analysis of CD4 T-cells within the periphery of individuals
provides molecular understanding to the initial quality of the
T-cell response against 5T4-derived antigens. Moreover, anal-
ysis ofwhich 5T4-derived peptides trigger cognateT-cells lends
insight into the factors that enable immunogenicity.
We generated CD4 T-cell clones restricted to commonly
recognized immunogenic 5T4 peptides presented on HLA-
DR1 (20). These clones produced a specific TH1 type response
to antigen in vitro, yet were weakly sensitive compared with
virus-reactive clones and exhibitedweak/no detectable engage-
ment of cognate ligand by multimer staining or surface plas-
mon resonance. Our data highlight that, at the clonal level,
despite the immunogenicity of these peptides, the quality, i.e.
sensitivity of the CD4T-cell response to such epitopes is poor
compared with nonself epitopes. This may reflect a thymic
selection process on self-antigens that deletes T-cells
responding to high affinity peptide ligands (31). Thymic
expression of 5T4 has indeed been shown in mouse at the
RNA level (32). Adequate peptide to HLA-DR1 binding
capacity was observed for two 5T4-derived peptides,
Figure 5.Highly focusedhot spot bindingbyGD.D104 is enabledbyPFRs.A, effect of alanine-substituted 5T4111–130 peptides onGD.D104 IFN- indicated
activation by ELISA. Substitution of Leu-7 and Asn-8 highlight a hot spot of reactivity by GD.D104 within the core-binding region. Peptide colors coded as
indicated (inset table). IFN- response normalized tomaximumWT20-mer response. Representative examples (mean S.D.) of two independent experiments
performed in at least duplicate is shown. B, effect of alanine-substituted 5T4111–130 peptides onHLA-DR1binding in in vitro competition assays. Representative
examples (mean S.D.) of two independent experiments performed in triplicate is shown. C, no IFN--indicated activation by GD.D104 to the nonamer core
peptide highlighting a requirement for PFRs. D, reduction in core 9-mer HLA binding compared with 20-mer. E, reduction in activation as a result of N-PFR
truncation. F,N-PFR truncation resulted in small reductions in HLA-DR1 binding. G, reduction in activation due to C-PFR truncation. H,minimal effect of C-PFR
on HLA-DR1 binding. I,modification (Gly113 Arg11) of C-PFR hairpin loop resulted in marginally increased activation andmaintenance of clone specificity. J,
minimal effect of PFR mutations on HLA-DR1 binding.
PFRs influence CD4 T-cell response to 5T4
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although binding was slightly weaker than pathogen-derived
peptides such as IAV-HA306–319. One 5T4 epitope exhibited
weak HLA-DR1 binding capacity that may in part explain the
relative poorer sensitivity of this cognate clone compared
with the two other 5T4-reactive clones in ELISA and
ELISPOT assays. Overall, the contribution of peptide-HLA
stability to the selection and sensitivity of anti-tumor CD4
clones should not be overlooked.
To focus our investigation, we were able to solve the struc-
ture of one of these epitopes (5T4111–130) bound by HLA-DR1
at high resolution, which defined the core binding nonamer.
Subsequently, alanine substitution of residues within this core
resulted in loss of clone reactivity. These modified peptides,
along with all mutated/truncated peptides of 5T4111–130
tested, were not predicted to induce new preferential bind-
ing motifs. It is therefore likely that loss of clone reactivity
was not as a result of epitope frame-shifting; suggesting
instead that the generated cognate clone focused binding to
a hot spot within the core peptide, where Leu-7 and Asn-8
were essential for immunogenicity.
Despite exhibiting highly focused binding to the epitope core
of 5T4111–130, the core peptide alone was insufficient to trigger
cognate clone activation in in vitro assays. This was coupled
with a significant decrease in peptide-HLA binding capacity
exhibited by the core alone compared with the 20-mer version.
Binding, however, still exceeded levels that will trigger T-cells,
suggesting a requirement of PFRs for optimal TCR-pHLA
interactions.
PFR requirement for immunogenicity is interesting given
our structural observations of the 5T4111–130 PFRs. We first
identified that HLA-DR1 can maintain considerable contact
with presented peptides between P3 and P12 positions. Such
contacts in the crystal structure suggest that a 15-mer peptide
may be optimal for HLA-DR1–5T4111–130 complex stability:
3-mer N-PFRs and 3-mer C-PFRs. Using cognate clone activa-
tion and HLA-DR1–binding assays, however, we show that
although truncation of the epitope outside these limits could
affect binding, the effects on T-cell activation weremore signif-
icant. A general optimal length for HLA-II binding has been
previously simulated at 18–20 amino acid length for a dataset
of antigenic HLA-II peptide sequences (33). By performingMD
simulations, we suggest that the PFRs of epitopes are highly
mobile and explore conformations: (i) toward the HLA-poten-
tially extending peptide-HLA contacts further outwards to PFR
extremities, and (ii) into space away from the HLA toward
potential TCR engagement.
Although the N-PFR made close contact to the HLA, the
C-PFR elevated away from the HLA surface volume and into
Figure 6. Conformations explored by PFRs of 5T4111–130 in MD simulations. A, representative snapshots from the 20 most populated clusters of the MD
trajectories illustrating peptide mobility. Backbone atoms of PFRs are shown as sticks and color-coded as indicated (inset). Core residues (all atoms) are blue
sticks with atom coloring as previous. DR (gray cartoon) and DR1 (purple cartoon) are represented from the static crystallographic structure. B, RMSF of
peptide C atoms. Mean S.D. as extracted from 10 independent MD simulations is shown. C, percentage of the total number of peptide to HLA contacts
(all-atoms including modeled hydrogens  3.0 Å) calculated from the MDs. D, three highlighted alternative PFR conformations represented in MDs.
Crystallographic peptide conformation is shown by pink sticks. Magnified visualization of boxed regions is shown in E-Hwith matched coloring accordingly. E,
extensionof contacts toArg-(4) throughbinding to -DR residuesobserved inMDsimulations. F,alternative conformationwherebyArg-(3) interactedwith
-DR residues inMDsimulations.G, representative extended conformationof Ser10–Leu14 extracted fromMDsimulationswhereby apotential flatteningof the
C-PFR hairpin loop allows contact with HLA residues in MDs. H, this suggested flattened conformation was enabled by inversion of dihedral angles about
Gly-11. I, distribution of backbone dihedral angles (	, ) of residues Ser-10(i1) and Gly-11(i2) extracted from the MDs. Ideal angles describing the crystallo-
graphic hairpin loop and flattened conformation are boxed in pink and red, respectively (40° deviation from ideals).
PFRs influence CD4 T-cell response to 5T4
20254 J. Biol. Chem. (2019) 294(52) 20246–20258
 at CA
RD
IFF U
N
IV
ERSITY
 on January 16, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
proximity of the peptide core. This elevation formed by a ST
loop was enabled through residue-specific peptide to peptide
interactions. A similar hairpin turn structure, a type II -turn
mediated by backbone interactions, has been described previ-
ously whereby, in this system, hairpin disruption resulted in
significant abrogation of cognate clone activation (6). In our
5T4111–130 system, despite a reduction in clone sensitivity to
C-PFR truncation, abrogation of GD.D104 clone activationwas
not as drastic as alteration of core binding hot spot residues, to
which the C-PFR was spatially located.
Interestingly, the 5T4111–130C-PFRs resembled that of native
whole protein antigen. Such refolding of peptide sequences in-
HLA is likely due to a loss of influence by the HLA, as shown by
diminishing peptide to HLA contacts to extended PFRs. Con-
sequently, inherent peptide folding geometry, due to native
whole protein amino acid composition, may no longer be
unraveled and pinned down through HLA presentation.
Thus, antigen processing may be tuned to create a peptide
ligandome, which allows the presentation of peptides that
benefit from PFR length enhanced immunogenicity while
limiting peptides to a length that is controllable by the
boundary of influence, i.e. the span of the peptide binding
groove of HLA-II molecules.
Given a dependence on PFRs to initiate any GD.D104
response to 5T4111–130 it may be reasonably assumed that TCR
engagement is sensitive to the structural features of 5T4111–130
PFRs. Mutation of a PFR residue designed to drastically alter
the PFRs structural composition, however, did not negatively
affect clone activation, instead showing a potential increase in
immunogenicity. In contrast, even a conservative (Leu3 Ala)
modification to a core residue of 5T4111–130 had little impact on
HLA binding but strikingly reduced cognate T-cell clonal
activation. Thus, cognate clone reactivity and specificity to
5T4111–130 was focused on core residues but enabled through
PFRs. This observation supports the notion that PFRs are an
amenable target to improve the immunogenicity of HLA-II–
restricted T-cells through modifications that enhance TCR
binding (4, 13, 34), whereas maintaining ligand specificity.
Moreover, relevant neo-antigens may be missed through
searching for core-only neo-epitopes without considering the
impact mutations within PFRs may have on TCR discrimina-
tion of antigens as nonself. Indeed, human thymic HLA-DR
peptide repertoires consist of PFR containing peptides, thus
PFRs may influence central tolerance (35). Further studies into
the impact of PFRs is warranted to decipher whether tumor-
epitopes may indeed be more dependent on PFR tuning, com-
pared with nonself systems, due to the weak sensitivity of the
5T4 CD4 T-cell response observed here at the clonal level.
We therefore envisage extended PFRs as highly mobile enti-
ties of HLA-II epitopes that make transient, but extremely
important, interactions with the HLA and TCR. Such transient
interactions may have a summative effect that tunes core-fo-
cused engagement by the TCR repertoire. Thus, this study
advances our understanding of the role PFRs play during T-cell
recognition, extends the definition of what constitutes an
HLA-II peptide epitope, and suggests PFRs could be targeted in
future therapies. Furthermore, unlike HLA-I where the peptide
is generally constrained within the peptide-binding cleft, the
open-ended groove of HLA-II enables the presentation of
natively folded protein conformations outside of the linear pep-
tide nonamer core. These data demonstrate that TCR recogni-
tion of pHLA-II is more complex than previously appreciated,
with interesting implications for pHLA-II–restrictedTCR anti-
gen specificity during CD4 T-cell–mediated immunity.
Experimental procedures
Generation and culture of T-cell clones
CD4 T-cell clones were generated using a T-cell library
cloning method outlined previously (22). PBMCs were isolated
from an HLA-DR1 donor, enriched for CD4 cells by mag-
netic microbead separation (Miltenyi Biotec), and expanded
using human T-activator CD3/CD28 Dynabeads (Life Tech-
nologies) at a cell to bead ratio of 1:2 for 14 days. Expanded cells
were screened for IFN- release in response to a pool of 5T4
candidate peptides (1 
 105 M) via enzyme-linked immuno-
spot assay (ELISpot) using T2-DR1 transduced cells as anti-
gen-presenting cells produced as described previously (22).
Peptide responsive lineswere pooled, expandedwith a 1
 105
M individual 5T4 peptide for 4 h before enrichment by IFN-
isolation (Miltenyi Biotec). The enriched line was tested for
reactivity to individual 5T4 peptide via IFN- ELISpot before
single cell cloning by serial dilution. The DCD10 clone was
generated and described previously (34).
Clones were maintained in culture at 3
 106 cells/ml in 10%
fetal calf serum, 2 mM L-glutamine, 100 IU/ml of penicillin, and
100 g/ml of streptomycin, 0.02 M HEPES, 1 mM nonessential
amino acids, 1 mM sodium pyruvate, and 200 IU/ml of human
recombinant IL-2 (Proleukin) media. T-cells were expanded
fortnightly using 1 g/ml of phytohemagglutinin (Alere,
Cheshire, UK), in the presence of irradiated (3100 gray) alloge-
neic PBMC feeder cells from three healthy donors.
Peptide-sensitivity assays
T-cell peptide activation assays were performed by co-cul-
turing T-cell clones with T2-DR1 cells as APCs in the presence
of WT or modified/truncated 5T4 peptides at a 2:1 APC to
T-cell ratio. Prior to the assay, T-cell clones were rested in
RPMI 1640 media, 5% fetal calf serum, 2 mM L-glutamine, 100
IU/ml of penicillin, and 100 g/ml of streptomycin overnight.
Serially diluted peptides were added to the co-culture and incu-
bated overnight at 37 °C, 5% CO2. Culture supernatants were
harvested for analysis of human IFN-, TNF, and MIP-1
using enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s protocol (R&D Systems). All ELISA data
were background subtracted using baseline cytokine/chemo-
kine response to no peptide controls, analyzed, and presented
usingmatplotlib (36).
Detection of T-cell activation by ELISpot assay
T-cell activation assays were performed by co-culturing pep-
tide-pulsed T2, T2-DR1, or autologous B lymphoblastoid cells
as APCs and activation was determined by a IFN- release
ELISpot assay (Mabtech). 5 
 106 APCs were pulsed at 37 °C,
5% CO2 for 2 h with 5T4 peptides (106-105 M) before wash-
ing twice with PBS. APCs were incubated with 10 g/ml of
PFRs influence CD4 T-cell response to 5T4
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anti-DR (L243 clone) antibody or media control for 1 h at 37 °C
and washed with PBS. APCs were then plated with 300 rested
GD.D104 T-cells onto prepared IFN- ELISpot plates, cultured
overnight, stained, and developed as per manufacturer’s
instructions and imaged using an ImmunoSpot analyzer (Cel-
lular Technology Limited).
Peptide-binding assays
Ability of peptides to bind HLA-DR1 molecules was deter-
mined by detection of competitive binding of candidatepeptides
to a biotinylated marker peptide (37). 60 l of peptide exchange
reactions were prepared in 20 mM MES, 140 mM NaCl, 0.02%
NaN3, pH 5 buffer with 0.1g of refoldedHLA-DR1-CLIP105–117
(SKMRMATPLLMQA), 4.5 nM N terminally biotinylated
CLIP99–117 (bt-LPKPPKPVSKMRMATPLLMQA) marker pep-
tide, and 10-fold serially diluted (104-1010 M in triplicate) can-
didate test peptide.Meanwhile,wells of half-areahigh-bindELISA
plates were incubated with 20 ng/l of anti-DR capture antibody
(L243 clone) in PBS (50 l). After overnight incubation (ELISA
plate at room temperature; peptide exchange at 37 °C), ELISA
plateswerewashedoncewithPBS, 0.02%Tween (PBS-T), blocked
with 3%BSA, PBS, 0.02%NaN3 (3%PBS) at room temperature for
1h, thenwashed (3
PBS-T, 3
PBS). Peptide exchange reactions
wereneutralizedusing1MTris, 10%BSA, 1%Tween, 0.02%NaN3,
pH 10, solution (10 l) and transferred (70 l) to the anti-DR–
coated ELISAplate. After 1 h 20min (room temperature), peptide
exchange reactions were discarded, plates were washed (3

PBS-T,3
PBS), then incubatedwithstreptavidin-HRP(diluted in
3%BSA-PBS solution according tomanufacturer’s recommended
dilution forELISAs) for20min (R&DSystems).Afterwashing (3

PBS-T, 3
 PBS), HLA-DR1 bound bt-CLIP marker peptide was
detectedusingHRPsubstrate (R&DSystems).Candidate test pep-
tide binding was evaluated by the ability to competitively inhibit
detected bound bt-CLIP marker compared with bt-CLIP marker
only controls (% competitive inhibition). Peptide-binding assays
were plotted usingmatplotlib and IC50 values were calculated by
fitting the four-parameter log(inhibitor) response function using
SciPy (33). PeptidebindingpredictionswereperformedusingNet-
MHCIIpan version 3.2 (26).
Generation of HLA-DR1molecules
HLA-DR1 molecules were in vitro refolded from inclusion
bodies as described previously (38). DR*0101 (Uniprot:
P01903, residues 26–207) and HLA-DR1*0101 (Uniprot:
P04229, residues 30–219) inclusion bodies were produced in
RosettaTM(DE3) competent BL21 strain-derived Escherichia
coli cells (Novagen). Prepared HLA-DR and -DR1 chain
inclusion bodies in 8 M urea, 20mMTris, pH 8.1, 0.5mM EDTA,
pH 8.1, were purified by Hi-Trap Q-Sepharose High Perform-
ance anion exchange chromatography using an AKTA Pure
FPLC (GE Healthcare Life Sciences).
To refold, 5mg/liter of each, HLA-DR and -DR1 inclusion
bodies were added to 25% glycerol, 20mMTris, 1mM EDTA, 20
mM NaCl, 1.48 g/liter of cysteamine hydrochloride, and 0.83
g/liter of cystamine hydrochloride supplemented with 0.5
mg/liter of peptide (Peptide Protein Research Ltd.) and stirred
vigorously for 1 h before incubation for 72 h at 4 °C. Refold
mixture was next buffer exchanged with PBS using 10 kDa
MWCO filtration units (Sartorius AG) and concentrated with
centrifugal filter units (Merck Millapore).
Conformational HLA-DR1molecules were purified using an
anti-DR (clone L243) antibody affinity purification column
produced using a PierceTM Protein A IgG Plus Orientation Kit
(ThermoFisher Scientific) eluting bound HLA-DR1 via 50 mM
CAPS, pH 11.5. Samples were further purified into 10 mM Tris,
10 mM NaCl, pH 8.1, via size exclusion chromatography (SEC)
using a Superdex 200HR gel SEC column (GE Healthcare Life
Sciences).
HLA-II multimer staining
Biotinylated HLA-DR1 molecules were refolded from inclu-
sion bodies as above with an additional C-terminal biotinyla-
tion signal sequence (GLNDIFEAQKIEWHE; AviTagTM)
ligated to theHLA-DRA*0101 sequence described, via a flexible
linker (GSGG). Refolded HLA-DR1 samples were biotinylated
using a BirA biotinylation kit (Avidity) and incubating over-
night at room temperature. Biotinylation efficiencywas assayed
by a SDS-PAGE streptavidin shift assay (39).
Multimers were assembled on the day of use by combining 2
l of phycoerythrin-labeled dextramer backbone (Immudex)
with 0.5 g of monomer per stain. T-cells were treated with
dasatinib as described previously (23) before staining withmul-
timer for 30min on ice.Multimer stainingwas boosted using an
anti-phycoerythrin secondary antibody as described previously
(24). Cells were then stained for viability using LIVE/DEAD
Fixable Violet Dead Cell Stain (Invitrogen) and surface CD4
expression (CD4-APC). Stained cells were analyzed on a
FACS Canto II (BD Biosciences) and data were evaluated in
FlowJo (Tree Star Inc.).
Protein crystallization, diffraction, andmodel refinement
HLA-DR1–5T4111–130 crystals were grown using sitting
drop vapor diffusion and crystal microseed hanging drop vapor
diffusion. Initial screening plates were performed using an Art-
Robbins Gryphon robot (Art Robbins Instruments, LLC.) by
dispensing 200 nl of protein into 200 nl of reservoir candidate
screen solution and incubation at 18 °C. Nondiffracting HLA-
DR1–5T4111–130 crystals were harvested for production of
crystal microseeds using a Seed BeadTM Kit (Hampton
Research Corp.). HLA-DR1–5T4111–130 crystals were grown in
0.02 M sodium/potassium phosphate, 0.1 M Bistris propane, pH
7.5, 20% PEG 3350 solution in the presence of combined HLA-
DR1–5T4111–130 microseeds grown in conditions detailed in
Table S2 and Fig. S6 via manually set drops (1 l of reservoir
solution, 1.5 l of protein sample, and 0.5 l of microseed
stock).
Cryopreserved crystals were exposed to X-rays and their dif-
fraction recorded at Diamond Light Source (Oxfordshire, UK)
at 100 K using a wavelength of 0.9795 Å. Observed reflection
intensities were estimated using XIA2 (40), and data were ana-
lyzed with AIMLESS and the CCP4 package (41). Phases were
obtained with molecular replacement using PHASER (42).
Models were refined using graphical manipulation in COOT
(43) and computationally refined through iterative TLS and
conjugate gradient refinement using REFMAC5 (44) until
convergence. Graphical representations were prepared using
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PyMOL (45). Contact tables were generated using NCONT
(CCP4). Reflection data and final model coordinates were
deposited to the Protein Data Bank under the code 6HBY.
Molecular dynamics simulations
Two simulation systems were prepared based on the two
molecules resolved in the crystal structure of the HLA-DR1–
5T4111–130 complex. The unresolved N-terminal residues of
HLA-DR1 and 5T4111–130 were modeled at extended confor-
mations to avoid steric clashes. Protonation states were calcu-
lated for physiologically relevant conditions (pH 7.4 and I 
0.15M) using theH server (46). Both systemswere solvated
into truncated octahedral boxes with TIP3P waters extending
up to 12 Å around the solute and the appropriate number of
Na to neutralize the total charge of each system were added.
AMBER ff14SB force field parameters (47) were applied using
the LEaP module of AMBER version 16 (48).
Molecular dynamics simulations were carried out using the
GPU-accelerated version of PMEMD(49), employing the equil-
ibration protocol and parameters as previously described (50).
Five independent production runs for each system were per-
formed in the isothermal isobaric ensemble at 310 K for 200 ns,
yielding an aggregate of 2,000 ns. A subset of 20,000 structures
sampled every 0.1 ns were clustered using a hierarchical
agglomerative approach with a minimum distance between
clusters of 2.5 Å, after mass-weighted, root mean square devia-
tion fitting of the HLA-DR1 C atoms using the CPPTRAJ
module of AmberTools version 16 (51).
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